ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1119

Uncontrolled Gout Patients with Higher Heart Failure Hospitalization Rates in US

Robert Morlock1, Pierre Chevalier2, An-Chen Fu3 and Douglas C.A. Taylor3, 1YourCareChoice, Ann Arbor, MI, 2IMS Health, Zaventem, Belgium, 3Ironwood Pharmaceuticals, Inc., Cambridge, MA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: gout, Heart disease, hyperuricemia and risk assessment

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Metabolic and Crystal Arthropathies Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by elevated serum uric acid (sUA). Elevated sUA is associated with worsened outcomes in patients with heart failure, however, little is known about the association between gout and acute heart failure (AHF). The objective of this study was to assess the impact of gout control on the rate of hospitalization for AHF in a prevalent gout population.

Methods: A retrospective analysis using the IMS Pharmetrics Plus database from 01/01/2009 to 12/31/2011. Patients were required to have evidence of “prevalent established gout” (ie, treated with urate-lowering therapy [ULT] or eligible for ULT based on American College of Rheumatology [ACR] guidelines) between 01/01/2009 and 12/31/2009, be aged ≥18 years on index date (01/01/2010), and have ≥1 sUA measurement reported during the year of evaluation of gout control status. Follow-up extended from 01/01/2010 to 12/31/2011. AHF rate was calculated as percentage of eligible patients having ≥1 AHF-related hospitalization over the course of calendar year 2011. In a given calendar year, patients were considered to have controlled gout if they had no elevated sUA (≥6 mg/dL), no diagnosis of tophus, and no flare documented, while uncontrolled gout was defined as ≥1 elevated sUA or ≥1 tophus diagnosis. The odds ratio (OR) of AHF was modeled using multivariable logistic regression adjusting for gout control status (in previous or current year), gender, age, and Charlson Comorbidity index as covariates.

Results: A total of 2,556 eligible gout patients with available sUA data in 2011 were identified in the US of which 67% had uncontrolled gout status (n=1,720). The unadjusted AHF hospitalization rates were 1.51% (95% confidence interval [CI]: 0.93%-2.09%) in patients with uncontrolled gout in 2011 and 0.72% (95% CI: 0.14%-1.29%) in patients with controlled gout. After adjusting for the covariates, AHF rate was significantly higher in patients whose gout was uncontrolled during the same year (adjusted OR: 2.66 [P=0.037]). Among the patients with available sUA data in 2010 (n=2,200), there was a trend indicating that patients with uncontrolled gout in 2010 were at higher risk of AHF hospitalization in 2011 (adjusted OR: 2.54 [P=0.059]).

Conclusion: This study suggests that patients with uncontrolled gout have a higher risk of being hospitalized for AHF. Further studies would be required to validate this finding on larger samples with availability of sUA data.


Disclosure: R. Morlock, Ironwood Pharmaceuticals, 5; P. Chevalier, IMSHealth, 3; A. C. Fu, Ironwood Pharmaceuticals, 1,Ironwood Pharmaceuticals, 3; D. C. A. Taylor, Ironwood Pharmaceuticals, 1,Ironwood Pharmaceuticals, 3.

To cite this abstract in AMA style:

Morlock R, Chevalier P, Fu AC, Taylor DCA. Uncontrolled Gout Patients with Higher Heart Failure Hospitalization Rates in US [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/uncontrolled-gout-patients-with-higher-heart-failure-hospitalization-rates-in-us/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/uncontrolled-gout-patients-with-higher-heart-failure-hospitalization-rates-in-us/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology